他泽司他治疗INI1/SMARCB1缺失的晚期上皮样肉瘤:国际开放标签2期篮式研究
该国际开放标签2期篮式研究纳入62例INI1/SMARCB1缺失的晚期上皮样肉瘤患者,评估口服EZH2抑制剂他泽司他800mg每日两次的疗效与安全性。
要点
- 他泽司他在INI1缺失的晚期上皮样肉瘤中客观缓解率达15%。
- 常见≥3级治疗相关不良事件为贫血(6%)和体重下降(3%)。
核心结论
- 他泽司他耐受性良好,在INI1/SMARCB1缺失的晚期上皮样肉瘤患者中显示出临床活性。
研究设计与样本
- 国际多中心开放标签2期篮式研究,纳入62例≥16岁、组织学确诊的局部晚期或转移性上皮样肉瘤患者,ECOG评分0-2,经免疫组化证实INI1表达缺失或SMARCB1双等位基因改变。
- 患者接受他泽司他800mg口服每日两次,连续28天为一周期,直至疾病进展、不可耐受毒性或撤回知情同意。
- 主要终点为研究者根据RECIST 1.1评估的客观缓解率,次要终点包括缓解持续时间、32周疾病控制率、无进展生存期、总生存期等。
主要发现
- 62例可评估患者中,9例(15% [95% CI 7-26])获得客观缓解。
- ≥3级治疗相关不良事件包括贫血(4例 [6%])和体重下降(2例 [3%]),治疗相关严重不良事件2例(癫痫和咯血各1例),无治疗相关死亡。
临床怎么用
- 对于INI1/SMARCB1缺失的晚期上皮样肉瘤,他泽司他可作为一种耐受性良好的靶向治疗选择。
- 治疗期间需监测贫血和体重下降等不良事件。
局限性
- 本研究为单臂2期研究,样本量有限(62例),无对照组。
- 主要终点为研究者评估的客观缓解率,可能存在评估偏倚。
- 随访时间较短,中位缓解持续时间尚未达到。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Epithelioid sarcoma is a rare and aggressive soft-tissue sarcoma subtype. Over 90% of tumours have lost INI1 expression, leading to oncogenic dependence on the transcriptional repressor EZH2. In this study, we report the clinical activity and safety of tazemetostat, an oral selective EZH2 inhibitor, in patients with epithelioid sarcoma. METHODS: In this open-label, phase 2 basket study, patients were enrolled from 32 hospitals and clinics in Australia, Belgium, Canada, France, Germany, Italy, Taiwan, the USA, and the UK into seven cohorts of patients with different INI1-negative solid tumours or synovial sarcoma. Patients eligible for the epithelioid sarcoma cohort (cohort 5) were aged 16 years or older with histologically confirmed, locally advanced or metastatic epithelioid sarcoma; documented loss of INI1 expression by immunohistochemical analysis or biallelic SMARCB1 (the gene that encodes INI1) alterations, or both; and an Eastern Cooperative Oncology Group performance status score of 0-2. Patients received 800 mg tazemetostat orally twice per day in continuous 28-day cycles until disease progression, unacceptable toxicity, or withdrawal of consent. The primary endpoint was investigator-assessed objective response rate measured according to the Response Evaluation Criteria in Solid Tumors, version 1.1. Secondary endpoints were duration of response, disease control rate at 32 weeks, progression-free survival, overall survival, and pharmacokinetic and pharmacodynamic analyses (primary results reported elsewhere). Time to response was also assessed as an exploratory endpoint. Activity and safety were assessed in the modified intention-to-treat population (ie, patients who received one or more doses of tazemetostat). This trial is registered with ClinicalTrials.gov, NCT02601950, and is ongoing. FINDINGS: Between Dec 22, 2015, and July 7, 2017, 62 patients with epithelioid sarcoma were enrolled in the study and deemed eligible for inclusion in this cohort. All 62 patients were included in the modified intention-to-treat analysis. Nine (15% [95% CI 7-26]) of 62 patients had an objective response at data cutoff (Sept 17, 2018). At a median follow-up of 13·8 months (IQR 7·8-19·0), median duration of response was not reached (95% CI 9·2-not estimable). 16 (26% [95% CI 16-39]) patients had disease control at 32 weeks. Median time to response was 3·9 months (IQR 1·9-7·4). Median progression-free survival was 5·5 months (95% CI 3·4-5·9), and median overall survival was 19·0 months (11·0-not estimable). Grade 3 or worse treatment-related adverse events included anaemia (four [6%]) and weight loss (two [3%]). Treatment-related serious adverse events occurred in two patients (one seizure and one haemoptysis). There were no treatment-related deaths. INTERPRETATION: Tazemetostat was well tolerated and showed clinical activity in this cohort of patients with advanced epithelioid sarcoma characterised by loss of INI1/SMARCB1. Tazemetostat has the potential to improve outcomes in patients with advanced epithelioid sarcoma. A phase 1b/3 trial of tazemetostat plus doxorubicin in the front-line setting is currently underway (NCT04204941). FUNDING: Epizyme.
引用
- Gounder M, Schöffski P, Jones RL, et al. Tazemetostat in advanced epithelioid sarcoma with loss of INI1/SMARCB1: an international, open-label, phase 2 basket study. Lancet Oncol. 2020. PMID: 33035459. doi:10.1016/S1470-2045(20)30451-4
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。